Bifogade filer
PDF
Kurs
-0,14%
Likviditet
0,07 MSEK
Kalender
| Tid* | ||
| 2025-11-27 | 15:00 | Kvartalsrapport 2025-Q3 |
| 2025-08-29 | 15:00 | Kvartalsrapport 2025-Q2 |
| 2025-05-22 | 15:00 | Kvartalsrapport 2025-Q1 |
| 2025-02-28 | 16:30 | Bokslutskommuniké 2024 |
| 2024-11-21 | - | Kvartalsrapport 2024-Q3 |
| 2024-08-22 | - | Kvartalsrapport 2024-Q2 |
| 2024-05-16 | - | Kvartalsrapport 2024-Q1 |
| 2024-05-15 | - | Årsstämma |
| 2024-03-22 | - | X-dag ordinarie utdelning KLAR 0.00 SEK |
| 2024-03-01 | - | Bokslutskommuniké 2023 |
| 2023-11-24 | - | Kvartalsrapport 2023-Q3 |
| 2023-08-25 | - | Kvartalsrapport 2023-Q2 |
| 2023-05-12 | - | Årsstämma |
| 2023-05-12 | - | Kvartalsrapport 2023-Q1 |
| 2023-03-25 | - | X-dag ordinarie utdelning KLAR 0.00 SEK |
| 2023-02-10 | - | Bokslutskommuniké 2022 |
| 2022-11-18 | - | Kvartalsrapport 2022-Q3 |
| 2022-08-26 | - | Kvartalsrapport 2022-Q2 |
| 2022-05-12 | - | Kvartalsrapport 2022-Q1 |
| 2022-03-25 | - | X-dag ordinarie utdelning KLAR 0.00 SEK |
| 2022-03-24 | - | Årsstämma |
| 2022-02-10 | - | Bokslutskommuniké 2021 |
| 2021-12-30 | - | Extra Bolagsstämma 2021 |
| 2021-10-28 | - | Kvartalsrapport 2021-Q3 |
| 2021-08-19 | - | Kvartalsrapport 2021-Q2 |
| 2021-05-21 | - | Kvartalsrapport 2021-Q1 |
| 2021-03-18 | - | Årsstämma |
| 2021-03-08 | - | X-dag ordinarie utdelning KLAR 0.00 SEK |
| 2021-02-12 | - | Bokslutskommuniké 2020 |
| 2020-11-26 | - | Kvartalsrapport 2020-Q3 |
| 2020-11-02 | - | Extra Bolagsstämma 2020 |
| 2020-08-28 | - | Kvartalsrapport 2020-Q2 |
| 2020-05-20 | - | Kvartalsrapport 2020-Q1 |
| 2020-04-29 | - | X-dag ordinarie utdelning KLAR 0.00 SEK |
| 2020-04-24 | - | Årsstämma |
| 2020-02-28 | - | Bokslutskommuniké 2019 |
| 2019-12-18 | - | Extra Bolagsstämma 2019 |
| 2019-11-15 | - | Kvartalsrapport 2019-Q3 |
| 2019-08-29 | - | Kvartalsrapport 2019-Q2 |
| 2019-05-23 | - | Kvartalsrapport 2019-Q1 |
| 2019-04-29 | - | X-dag ordinarie utdelning KLAR 0.00 SEK |
| 2019-04-26 | - | Årsstämma |
| 2019-02-21 | - | Bokslutskommuniké 2018 |
| 2018-11-27 | - | Kvartalsrapport 2018-Q3 |
| 2018-08-28 | - | Kvartalsrapport 2018-Q2 |
| 2018-05-24 | - | Kvartalsrapport 2018-Q1 |
| 2018-04-23 | - | X-dag ordinarie utdelning KLAR 0.00 SEK |
| 2018-04-20 | - | Årsstämma |
| 2018-02-28 | - | Bokslutskommuniké 2017 |
| 2017-11-24 | - | Kvartalsrapport 2017-Q3 |
| 2017-08-28 | - | Kvartalsrapport 2017-Q2 |
| 2017-06-02 | - | X-dag ordinarie utdelning KLAR 0.00 SEK |
| 2017-05-29 | - | Kvartalsrapport 2017-Q1 |
| 2017-04-26 | - | Årsstämma |
| 2017-02-28 | - | Bokslutskommuniké 2016 |
| 2016-11-17 | - | Kvartalsrapport 2016-Q3 |
| 2016-08-25 | - | Kvartalsrapport 2016-Q2 |
| 2016-05-27 | - | Årsstämma |
| 2016-05-19 | - | Kvartalsrapport 2016-Q1 |
| 2016-03-01 | - | X-dag ordinarie utdelning KLAR 0.00 SEK |
| 2016-02-26 | - | Bokslutskommuniké 2015 |
| 2015-11-29 | - | Kvartalsrapport 2015-Q3 |
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Bioteknik |
Klaria Year-End Report 1 January-31 December 2022 Q4 2022
Summary of the Year-End Report
Successful rights issue brought 59.2 MSEK to Klaria
New collaboration agreement signed with PharmaMar fourth quarter of 2022
- Net sales amounted to 2.2 MSEK (0.0 MSEK)
- Other income amounted to 0.2 MSEK (6.2 MSEK)
- R&D costs for the period amounted to 8.6 MSEK (28.1 MSEK)
- Profit after tax amounted to -12.9 MSEK (-24.8 MSEK)
- Earnings per share for the quarter amounted to -0.22 SEK (-0.48 SEK)
- Cash flow from operating activities amounted to -10.7 MSEK (-14.6 MSEK)
- Cash and cash equivalents on the balance sheet date amounted to 16.8 MSEK (25.5 MSEK)
- Equity as of December 31 amounted to 76.0 MSEK (69.4 MSEK) The period January-December 2021
- Net sales amounted to 5.9 MSEK (0.0 MSEK)
- Other income amounted to 0,7 MSEK (37.5 MSEK)
- R&D costs for the period amounted to 51.4 MSEK (63.5 MSEK)
- Profit after tax amounted to -63.8 MSEK (-53.5 MSEK)
- Earnings per share for the quarter amounted to -1.10 SEK (-1.03 SEK)
- Cash flow from operating activities amounted to -49.8 MSEK (-24.8 MSEK)
- Cash and cash equivalents in the parent company amounted to 15.5 MSEK (9.1 MSEK)
- Equity in the parent company amounted to 175.3 MSEK (158.4 MSEK)
Jesper Wiklund, CEO Klaria Pharma Holding AB (publ)
investor.relations@klaria.com (scott.boyer@klaria.com)
Tel: +46 (0) 8-446 42 99